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The human immune system depends on the activity of cytotoxicT lymphocytes (CTL), nat-
ural killer (NK) cells, and NKT cells in order to fight off a viral infection. Understanding the
molecular mechanisms during this process and the role of individual proteins was greatly
improved by the study of familial hemophagocytic lymphohistiocytosis (FHL). Since 1999,
genetic sequencing is the gold standard to classify patients into different subgroups of FHL.
The diagnosis, once based on a clinical constellation of abnormalities, is now strongly sup-
ported by the results of a functional flow-cytometry screening, which directs the genetic
study. A few additional congenital immune deficiencies can also cause a resembling or
even identical clinical picture to FHL. As in many other rare human disorders, the collection
and analysis of a relatively large number of cases in registries is crucial to draw a complete
picture of the disease.The conduction of prospective therapeutic trials allows investigators
to increase the awareness of the disease and to speed up the diagnostic process, but also
provides important functional and genetic confirmations. Children with confirmed diagno-
sis may undergo hematopoietic stem cell transplantation, which is the only cure known to
date. Moreover, detailed characterization of these rare patients helped to understand the
function of individual proteins within the exocytic machinery of CTL, NK, and NKT cells.
Moreover, identification of these genotypes also provides valuable information on variant
phenotypes, other than FHL, associated with biallelic and monoallelic mutations in the
FHL-related genes. In this review, we describe how detailed characterization of patients
with genetic hemophagocytic lymphohistiocytosis has resulted in improvement in knowl-
edge regarding contribution of individual proteins to the functional machinery of cytotoxic
T- and NK-cells.The review also details how identification of these genotypes has provided
valuable information on variant phenotypes.
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INTRODUCTION
Defense of an organism against pathogens and cancer is accom-
plished by the cooperation between different cell types of the
human immune system, in particular cytotoxic T lymphocytes
(CTL), natural killer (NK) cells, and NKT cells (1). Although
these cells use different receptors to identify a target cell, once
activated they all employ a similar, highly coordinated machinery
that delivers the lethal hit by the secretion of secretory lyso-
somes (2). Secretory lysosomes in CTL, NK, and NKT cells are
lysosome-related organelles that contain perforin, a tetrameric
protein, which is able to form pores across lipid bilayers and serine
proteases, such as granzymes. Upon release of perforin into the gap
formed between the effector and target cell, perforin pores allow
granzymes to enter the target cell and to trigger apoptosis by ini-
tiation of the caspase cascade (3). Although in this review we will
address more specifically some features of the NK cells, because
they are suitable for rapid diagnostic assays, it is important to
recognize that T-cells share most of these features and have great
relevance in most of the human disease related to impairment of
this machinery.
Natural killer cells serve as pivotal sentinels within the immune
system as they respond quickly to a pathogenic infiltration and
alert the host about infections. They are able to recognize and
lyse tumor cells and virus-infected cells, even without any pre-
vious sensitization. NK cells originate in the bone marrow and
are released into the bloodstream upon maturation, thus being
able to respond to stimuli such as pathogen molecules, cytokines,
or by the interaction with any target cell that expresses ligands
for activating NK cell receptors. Since inhibitory receptors recog-
nize the ubiquitously expressed MHC class I molecules, NK cells
do not attack healthy cells. On the contrary, NK cell activation
occurs when a potential target cell lacks surface MHC class I, as
observed in cancer or infection. This concept has been defined
as the “missing self-hypothesis.” As a result, NK cells behave as
fine-tunable effector cells: their regulation may occur at different
levels, since the number of receptors which are expressed on their
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surface may be modified according to the level and type of circulat-
ing cytokines. The balance of signals received from activating and
inhibitory receptors determines the outcome of NK cell function.
Furthermore, an increasing interest is directed to the interaction
(cross-talk), which occurs between NK cells and other cells engaged
in the early phase of inflammatory response (4), which have major
implications for the ability of the organism to react to infection
and cancer.
Activation and priming of cytotoxic T- and NK-cells induces
the formation of secretory lysosomes, which contain lytic mole-
cules. The complex machinery of handling and re-locating these
granules became more readable by investigation of human exper-
imental models represented by a congenital immune deficiency in
which defective granules activity has a pivotal pathogenic role.
HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS
Hemophagocytic lymphohistiocytosis (HLH) is a hyper-
inflammatory syndrome observed more often, but not exclusively,
in children. Accumulation of reported cases and investigation
of consanguineous families allowed to define that the famil-
ial form of HLH is indeed a congenital immune deficiency; to
date, four subtypes are defined by mutations in the following
genes: PRF1 in familial hemophagocytic lymphohistiocytosis type
2 (FHL2), UNC13D in familial hemophagocytic lymphohistiocy-
tosis type 3 (FHL3), STX11 in familial hemophagocytic lympho-
histiocytosis type 4 (FHL4), and STXBP2 in familial hemophago-
cytic lymphohistiocytosis type 5 (FHL5). These subtypes will be
described below in more details. Furthermore, some patients with
other congenital immune deficiencies [X-linked lymphoprolif-
erative disorder, Griscelli syndrome, Chédiak–Higashi syndrome
(CHS), and Hermansky–Pudlak syndrome (HPS)] may develop
HLH. A fully overlapping clinical picture may be observed, most
often following viral infection, in patients with no evidence of
genetic defect; these cases have been usually defined as “sec-
ondary” or HLH. Patients with HLH are often older than those
with underlying genetic defect, but the clinical course may be
equally life-threatening. The approach to patients with HLH/FHL
is aimed at achieving clinical remission while defining the diag-
nosis. Definition of FHL has immediate therapeutic implica-
tions inasmuch hematopoietic stem cell transplantation (HSCT)
is mandatory for FHL, but not for HLH, with the only excep-
tion of those cases in which the disease recurs and proves to be
familial (and potentially linked to other or unknown genes) or
treatment-dependent.
FAMILIAL HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS
Familial hemophagocytic lymphohistiocytosis is a genetically het-
erogeneous disorder caused by mutations in genes involved in
the secretory lysosome-dependent exocytosis pathway. More than
60 years after the first FHL case was reported, five independent,
FHL-causing loci have been identified and the underlying genetic
defect has been described for four of them (Table 1). Moreover, we
have progressively learned that other immune deficiencies have a
clinical picture that may initially lead to a diagnosis of FHL. The
genes involved are numerous and some of them are difficult to
analyze due to the size of the gene and heterogeneity of muta-
tions. Yet, around 70% of cases are explained by mutations in only
two genes: PRF1 and UNC13D, which cause the FHL2 and FHL3
subgroups, respectively (5).
FAMILIAL HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS TYPE 2 (OMIM
603553)
Nearly 15 years after its genetic definition, it is now clear that FHL2
accounts for 20–50% of all FHL cases, depending on the cohort
studied (7–9). Mutations in the perforin gene (PRF1, OMIM
170280) are responsible for this phenotype (8–10). PRF1 has
three exons: exon 2 and 3 code a 555 amino-acid polypeptide.
Over 120 different mutations have been identified to date: 101
missense/non-sense mutations and 21 deletion/insertion muta-
tions (8, 10–17). Since the pathogenic role of some mutations,
especially some single amino-acid substitutions, is difficult to
assess, their functional characterization is still required. In a recent
comprehensive in silico analysis of 76 missense mutations in PRF1,
An et al. used a structural approach to explain the effect of a
mutation on the ability of perforin to oligomerize, thereby offer-
ing an explanation for the observed defect in cytotoxicity in FHL2
patients (18).
Accumulation of a sufficient number of cases helped to estab-
lish connections between specific mutations and particular eth-
nic groups: c.1122G>A (p.W374X) was found to have a high
Table 1 | Overview of some characteristics of genetic disorders associated with occurrence of hemophagocytic lymphohistiocytosis.
Subtype OMIM number Mutated gene Locus Affected protein Animal model
FHL1 603552 9q21.3–22 Unknown None
FHL2 267700 PRF1 9q21.3–q22 Perforin Pfn1−/−
FHL3 608898 UNC13D 17q25.1 Munc13-4 Jinx
FHL4 603552 STX11 6q24 Syntaxin 11 None
FHL5 613101 STXBP2 19p13 Munc18-2 None
GS2 (Griscelli) 607624 RAB27A 15q21 RAB27a Ashen
CHS (Chédiak–Higashi) 214500 LYST 1q42.1–q42.2 LYST Beige
HPS2 (Hermansky–Pudlak) 608233 ADTB3A 5q14.1 AP-3 Pearl
XLP-1 308240 SH2D1A Xp25 SAP Sh2d1a−/−
XLP-2 300635 XIAP Xp25 XIAP XIAP-ps1−/−*
*The XIAP-ps1−/− knockout mouse described in 2009 by Kotevski et al. did not phenocopy the XLP-2 human disease [Ref. (6)].
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incidence in Turkish patients (9); mutation c.50delT (p.L17FsX)
is very frequent in patients of African-American origin (19);
while the c.1090-1091delCT (p.L364fsX) mutation has only been
identified in Japanese patients (10).
Mutation c.272C>T (p.A91V) has a particularly high fre-
quency in Southern European population, ranging from 2.5 up
to 10% (20, 21). It seems to be present at a very low fre-
quency in African-American subjects and Sub-Saharan Africans,
with no reported cases of the polymorphism in Japan, sup-
porting the concept of a Mediterranean origin of the muta-
tion. Although its impact on the protein structure and func-
tion has been documented (22, 23), its pathogenic role in
FHL has been considered controversial. It is now clear that
patients with FHL2 frequently show A91V mutation in com-
bination with another pathogenic mutation; association of
A91V with another missense/hypomorphic mutation frequently
results in a late-onset of FHL2 (24). Interestingly, in addi-
tion to the 106 mutations described in FHL2 patients, other
mutations have been associated with different phenotypes (see
below).
FAMILIAL HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS TYPE 3 (OMIM
608898)
Familial hemophagocytic lymphohistiocytosis type 3 is caused
by mutations in the UNC13D gene (OMIM 608897), which
encodes the 1,090 amino-acids-long protein Munc13-4. Munc13-
4 is involved in the priming of secretory granules and their fusion
with the plasma membrane, and its loss-of-function consequently
impairs the release of perforin and granzyme into the synaptic
cleft (25).
Familial hemophagocytic lymphohistiocytosis type 3 covers
between 30 and 40% of FHL patients, based on different geo-
graphic areas and ethnic groups. The clinical picture of FHL3
patients is undistinguishable from that of FHL2 patients. However,
evaluation of patient CTL and NK cells by flow-cytometry showed
a clear difference: while FHL2 patients have no perforin but show
no degranulation defect, cells from FHL3 patients have normal
perforin expression but reduced to absent degranulation (26)
(Table 2).
UNC13D consists of 32 coding exons. To date at least
112 different mutations in UNC13D have been reported as a
cause of FHL3: 60 missense/non-sense, 25 splicing/regulatory,
25 deletion/insertion mutations, as well as 2 complex gene
rearrangements (25–28). After some initial difficulties in rec-
ognizing biallelic mutations in patients with FHL3, it became
evident that not only exonic mutations, but also variations
outside exons and splice sites are a common cause of FHL3
(29). Since then, additional contribution confirmed this issue.
In 2011, Meeths et al. described two novel mutations frequently
occurring in Northern European populations: the deep intronic
mutation c.118-308G>A selectively impairs UNC13D transcrip-
tion in lymphocytes, thus abolishing Munc13-4 expression while
the 253-kb inversion affects the 3′-end of the transcript, also
abolishing Munc13-4 expression (30). Another deep intronic
mutation, c.118-307G>A, was recently reported in a Chinese
patient and documented to impair UNC13D transcription, possi-
bly by disrupting a transcription factor binding-site or enhancer
element (31). Two mutations have been described in specific
populations: the c.1596+ 1G>C mutation is described as the
most common UNC13D mutation in Japan (29) while muta-
tion c.754-1G>C is predominantly found in Korean patients
(32). Altogether, the mutation analysis of patients with FHL3
turned out to be far more engaging than that of patients with
FHL2.
Recently in a genotype–phenotype study of 84 patients with
FHL3 from Italy, Germany, and Sweden, Sieni et al. described that
central nervous system (CNS) involvement is more common in
patients with FHL3 than with FHL2. Moreover, the combination
of fever, splenomegaly, thrombocytopenia, and hyperferritinemia
appears to be the most easily and frequently recognized clinical
pattern in FHL3, and in association with a defective granule release
assay may lead to clinical suspicion of FHL3 (28).
While FHL2 and FHL3 subgroups account for the majority
of patients with FHL, additional genetic subgroups have been
progressively identified.
FAMILIAL HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS TYPE 4 (OMIM
603552)
Familial hemophagocytic lymphohistiocytosis type 4 is caused by
mutations in the STX11 gene (OMIM 605014) (33). This gene con-
sists of two exons and encodes the 287 amino-acid-long SNARE
protein Syntaxin 11 (Stx11).
Table 2 | Overview of the functional characteristics of genetic disorders associated with occurrence of hemophagocytic lymphohistiocytosis.
Subtype Protein expression NK cell function Degranulation
FHL1 Unknown Unknown Unknown
FHL2 Perforin reduced to absent, detectable by flow-cytometry Defective killing Normal
FHL3 Munc13-4 defect, detectable by western blot Variably impaired Reduced
FHL4 Syntaxin 11 defect, detectable by western blot Variably impaired Reduced
FHL5 Munc18-2 defect, detectable by western blot Variably impaired Reduced
GS2 (Griscelli) Rab27a defect, detectable by western blot Variably impaired Reduced
CHS (Chédiak–Higashi) Lyst defect, detectable by western blot Variably impaired Reduced
HPS2 (Hermansky–Pudlak) AP-3 defect, detectable by western blot Variably impaired Reduced
XLP-1 SAP defect, detectable by flow-cytometry Inhibitory 2B4, defective vs. B-EBV Normal
XLP-2 XIAP defect, detectable by flow-cytometry (with limitations)
and western blot
Enhanced AICD Normal
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Although original reports of FHL4 were restricted to families
of Turkish/Kurdish origin, more recently patients of different ori-
gins have been identified with a defect in STX11. Despite the initial
clustering of cases, at least 12 different STX11 mutations have been
described to date: 5 missense/non-sense mutations, 5 small dele-
tions, 1 small deletion, and 1 gross deletion (34–36). Patients with
FHL4 seem to have a later onset and a less severe clinical presenta-
tion of the disease compared to FHL2 and FHL3 (37). Mutations
in STX11 have never been associated with variant phenotypes,
different from FHL4.
Recently, Sepulveda et al. tried to elucidate the role of STX11
mutations in the pathogenesis of FHL. They generated a Stx11-
deficient (Stx11−/−) murine model that faithfully reproduced the
manifestations of HLH and represented a suitable model for study-
ing FHL4 in vivo and the role of Stx11 in vitro. By comparing the
severity of HLH in Stx11−/−mice with that observed in Rab27a−/−
and Prf1−/− mice, they established a correlation between the
murine mutants and the age at HLH onset in their human coun-
terparts (38). Furthermore, in a recent report the STX11 L58P
mutation revealed that both the N-terminus and Habc domain
of Stx11 are required for binding to Munc18-2, implying simi-
larity to the dynamic binary binding of neuronal syntaxin 1 to
Munc18-1 (39).
FAMILIAL HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS TYPE 5 (OMIM
613101)
Familial hemophagocytic lymphohistiocytosis type 5 is due to
mutations in STXBP2 (also named MUNC18-2; OMIM 601717)
(40, 41) and has been reported to account for up to 20% of cases
with FHL in the German series (42). Since 2010, 40 different muta-
tions of STXBP2 have been described: 15 missense/non-sense, 10
splicing/regulatory, and 15 deletion/insertion mutations (41, 43–
46). FHL5 does not appear to be restricted to a specific geographic
region.
In contrast to what was observed for the comparison between
FHL2 and FHL3, some clinical presentations of FHL5 seem to be
different from other classical manifestations of FHL. Gastrointesti-
nal symptoms, such as chronic diarrhea, gastro-esophageal reflux,
and abdominal pain are present in a significant number of patients.
Renal tubular dysfunction was also observed in one patient. This
could be explained by an impaired expression and function of
Munc18-2/STXBP2 protein in cells other than cytotoxic lympho-
cytes, including intestinal and renal epithelium (47). The defect
caused by insufficient function of STXBP2 protein in the neu-
trophils is associated with defective mobilization of the granules.
As a result, the cell is unable to kill bacteria; insufficient clearance
of E. coli might be one or the main reason for the frequency of
gastrointestinal symptoms in patients with FHL5 (42, 46–48).
Since platelets contain syntaxin-binding proteins with non-
redundant functional roles, platelets from FHL5 patients have
defective secretion, with decreased Munc18-2 and Stx11 levels.
These data demonstrated a key role for Munc18-2, perhaps as a
limiting factor, in platelet exocytosis, suggesting that it regulates
Stx11 (49). These data together with those of Pagel et al. (41) sug-
gest that, although bleeding histories may be too variable to be a
sufficient diagnostic criteria, platelet function assays may be worth
investigating in patients with FHL.
ADDITIONAL GENETIC IMMUNE DEFICIENCIES ASSOCIATED
WITH HLH
In addition to the described four subgroups of FHL, in which HLH
is usually the primary manifestation, a few additional genetic con-
ditions may cause a clinical syndrome largely overlapping that of
FHL but in which additional, distinctive clinical features occur.
X-LINKED LYMPHOPROLIFERATIVE DISEASE 1 (DUNCAN DISEASE,
OMIM 308240)
X-linked lymphoproliferative disease 1 (XLP-1) is a rare congen-
ital immunodeficiency caused by mutations in SH2D1A (Xq25),
the gene encoding the signaling lymphocyte activation molecule
(SLAM)-associated protein (SAP) (50, 51).
In immune-competent individuals Epstein–Barr virus (EBV)
causes infectious mononucleosis, a common, usually self-limited
disease. In XLP-1, the lack (or dysfunction) of SAP causes
the selective inability to control infection by EBV, a γ-herpes
virus that infects B-cells (52–55). Several immunological defects
have been identified, including defective NK and CD8+ T-cell-
mediated cytolytic responses against EBV-infected cells, which
lead to B-cell accumulation and persistence of reactive inflam-
matory responses (56). In the absence of SAP, 2B4 receptor
(member of SLAM family), when engaged by its ligand CD48,
delivers inhibitory instead of activating signals (53). It has been
recently demonstrated that in XLP-1 NK cells the co-engagement
of 2B4 with different activating receptors inhibits NCR, CD16,
and activating KIRs, characterized by ITAM-dependent signal-
ing pathways. In contrast, the 2B4 dysfunction does not affect
the activity of DNAM-1 and NKG2D triggering receptors. Thus,
while CD48+ B-EBV and lymphoma B-cells devoid of NKG2D
and DNAM-1 ligands were resistant to lysis, the preferential
usage of these receptors allowed XLP-1 NK cells to kill lym-
phomas that expressed sufficient amounts of the specific ligands
(57). Better knowledge of the underlying dysfunction could be
turned into a diagnostic tool. Patients with XLP-1 may present
with different phenotypes: fulminant mononucleosis, B-cell lym-
phoma, lymphoproliferation, and dysgammaglobulinemia (56,
58, 59), but also with HLH (60). Thus, differential diagnosis
is relevant. To this issue, immunological screening for intra-
cytoplasmic SAP expression and rapid assays to examine 2B4
receptor function, which is inhibitory instead of activating in
SH2D1A mutated patients (53, 57), may be applied (Manuscript
in preparation).
In our review of the literature, 100 SH2D1A mutations were
found: 46 missense/non-sense, 14 splicing, 2 regulatory mutations,
9 small deletions, 6 small insertions, and 23 gross deletions (50–58,
61). Interestingly, this gene is characterized by a high number of
deletions including the entire gene. Intronic mutations have also
been described affecting SH2D1A transcription but not mRNA
splicing, and leading to markedly reduced level of SAP protein
(61). Thus, the strategy of mutation analysis of this gene must be
designed to include these possible variants.
X-LINKED LYMPHOPROLIFERATIVE SYNDROME TYPE 2 (OMIM 300635)
A subset of patients with an XLP-like phenotype was recently
found to have mutations in BIRC4, the gene encoding the X-
linked inhibitor of apoptosis protein (XIAP) and has been linked to
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another subgroup,named X-linked lymphoproliferative syndrome
type 2 (XLP-2) (62).
X-linked inhibitor of apoptosis protein is an essential ubiq-
uitin ligase for pro-inflammatory signaling downstream of the
nucleotide-binding oligomerization domain containing (NOD)-1
and -2 pattern recognition receptors. Recently, the XIAP bac-
ulovirus IAP repeat (BIR2) domain was recognized as a hotspot
for missense mutations in XLP-2. XLP-2-BIR2 mutations severely
impair NOD-1/2-dependent immune signaling in primary cells
from XLP-2 patients and in reconstituted XIAP deficient cell
lines. XLP-2-BIR2 mutations abolish the XIAP–RIPK2 interaction
resulting in impaired ubiquitylation of RIPK2 and recruitment of
linear ubiquitin chain assembly complex (LUBAC) to the NOD-
2-complex. These new findings document that impaired immune
signaling in response to NOD-1/2 stimulation is a general defect
in XLP-2 and demonstrate that the XIAP BIR2–RIPK2 inter-
action might be even targeted pharmacologically to modulate
inflammatory signaling (63).
In a comparison of the clinical phenotypes associated with XLP-
1 and XLP-2, EBV infection was the common trigger of HLH in
92% of XLP-1 and 83% of XLP-2. HLH (XLP-1, 55%; XLP-2,
76%) and hypogammaglobulinemia (XLP-1, 67%; XLP-2, 33%)
occurred in both groups, although with different proportions.
Survival rates and mean ages at the first HLH episode did not
differ for both groups, but HLH was more severe with lethal out-
come in XLP-1. Only XLP-1 patients developed lymphomas while
XLP-2 patients preferentially displayed chronic hemorrhagic col-
itis, recurrent splenomegaly often associated with cytopenia and
fever (64).
In a similar study, Marsh et al. reported an early dis-
ease onset during infancy for XLP-2-linked HLH and a high
relapse rate; however, this seemed to occur even in the
absence of an EBV infection. Some XLP-2 patients develop
hypo/dysgammaglobulinemia resulting from humoral immune
system derangement. Intriguingly, and in contrast to XLP-1,
XLP-2 was never associated with common variable immunode-
ficiency (64).
In a third consortium review of 25 patients, the majority ini-
tially presented with manifestations other than HLH, such as
Crohn-like bowel disease (n= 6), severe infectious mononucleo-
sis (n= 4), isolated splenomegaly (n= 3), uveitis (n= 1), periodic
fever (n= 1), fistulating skin abscesses (n= 1), and severe Giar-
dia enteritis (n= 1). Subsequent manifestations included celiac-
like disease, antibody deficiency, splenomegaly, and partial HLH.
Screening by flow-cytometry identified 14 of 17 patients in this
cohort (65). Given these clinical differences, XIAP deficiency must
be considered in a wide range of clinical presentations. It has
recently been suggested that XIAP deficiency would be better clas-
sified if defined as an X-linked subtype of FHL, rather than as a
second type of XLP (64).
To date, 41 mutations are known in BIRC4: 20 missense/non-
sense, 2 splicing mutations, 2 regulatory mutations, 16 dele-
tions/insertions, and 1 complex rearrangement (62, 64, 66, 67).
The phenotypic differences may be the result of differences in the
molecular basis of each disease. However, neither genotype, nor
protein expression, nor results from cell death studies were clearly
associated with the clinical phenotype.
Although HSCT remains the milestone for cure of FHL, some
discrepancy recently emerged in the outcome of patients with
XLP-2. In an international survey of 19 patients, 7 received mye-
loablative (MAC) regimens, 1 received an intermediate-intensity
regimen, and 11 received reduced intensity conditioning (RIC)
regimens predominantly consisting of alemtuzumab, fludarabine,
and melphalan. The probability of survival was very low in the
MAC group, with all but one patient dying from transplantation-
related toxicities (especially veno-occlusive disease and pulmonary
hemorrhage); otherwise, 55% of those who received RIC survived
at a median of 570 days after HSCT. The probability of surviving
in the RIC was enhanced by disease inactivity at the time of HSCT.
Based on these findings, MAC regimens should not be used for
patients with XIAP deficiency. The reason may be connected with
the loss of XIAP anti-apoptotic functions in XLP-2 patients (68).
IMMUNODEFICIENCIES ASSOCIATED WITH HLH AND PARTIAL
ALBINISM
At present three syndromes are known to cause HLH and manifest
with partial albinism.
CHÉDIAK–HIGASHI SYNDROME (OMIM 214500)
Around 85% of CHS patients develop HLH in the first decade of
life. They show markedly defective cytotoxicity of both NK cells
and CTL. The genetic defect is caused by mutations in the LYST
gene (69), which encodes a 3,801 amino-acid protein. Each clini-
cal manifestation of CHS (albinism, bleeding tendency, recurrent
bacterial infections, neurologic dysfunction, and HLH) (70, 71) is
associated with a defect of a specific cell type and the formation of
enlarged lysosomes in these cells.
The presence of giant inclusion bodies of lysosomal origin in a
variety of granule-containing cells, including hematopoietic cells
and melanocytes, has thus become the hallmark of the disease (72).
This feature together with HLH and oculo-cutaneous albinism can
address clinical suspicion toward CHS and direct molecular analy-
sis to LYST sequencing. In our revision of the available literature,
a total of 56 mutations were found to be reported at the time
of writing: 23 missense/non-sense, 4 splicing, 20 small deletions,
8 small insertions, and 1 gross deletion. As expected, disruptive
mutations correlated with the severe form of the disease (73).
The wider diffusion of mutation analysis, despite the big size of
the gene, provided an increased number of reports from different
geographic areas during the last few years, confirming that CHS
has no ethnic or geographic boundaries.
A rare neurologic disorder, named hereditary spastic paraplegia
(HSP) and characterized by leg spasticity, weakness, hyperreflexia,
and additional neurological symptoms, was recently reported in
two adult siblings with HSP and homozygous LYST pathogenic
mutation. Large peroxidase-positive granules were observed in
both patients’ granulocytes, while pigment deficiency, immune
deficiency, and bleeding tendency were not observed. This exam-
ple illustrates nicely how the clinical spectrum of CHS may be
much broader than recognized at present (74).
GRISCELLI SYNDROME TYPE 2 (OMIM 607624)
Griscelli syndrome is a rare autosomal-recessive disorder charac-
terized by partial oculo-cutaneous albinism and HLH (75). Among
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GS subtypes, only patients with type 2 develop HLH. Mutations
causing Griscelli syndrome type 2 (GS2) were mapped to the
RAB27A gene, which is composed of 5 coding exons and encodes
for a 221 amino-acid protein that belongs to the superfamily of
small Rab GTPase. CTLs and NK cell activity defect results from
the inability of cytotoxic granules to dock to the plasma membrane
whereas hypopigmentation is accounted for by a defective release
of melanosomes from melanocyte dendrites. Change in phagoso-
mal function and antigen cross-presentation of Rab27a-deficient
dendritic cells has been reported in vitro. In the mouse model
(ashen mice), the dendritic cells are unable to perform a sufficient
antigen cross-presentation (76).
To date 34 RAB27A mutations are known: 15 missense/non-
sense, 4 splicing, and 15 deletions/insertion. In 2010, Meeths et al.
sequenced RAB27A in patients diagnosed as HLH and found one
mutated family (77). Since the clinical picture of the two syn-
dromes is indistinguishable, they concluded that the diagnosis of
GS2 may be overlooked, particularly in fair-haired patients with
hemophagocytic syndromes.
HERMANSKY–PUDLAK TYPE 2 (OMIM 608233)
The term HPS encompasses nine different human autosomal-
recessive genetic disorders, sharing partial oculo-cutaneous
albinism and bleeding disorders (78, 79). Furthermore, patients
with Hermansky–Pudlak type 2 (HPS2) also show an increased
susceptibility to infections, resulting from both congenital neu-
tropenia and impaired cytotoxic activity. Mutations of the gene
encoding the β-3A subunit of adaptor protein-3 (AP-3) complex
are the cause of HPS2 (80). To date, 20 mutations are known in
this gene and are associated with HPS2: 7 missense/non-sense,
1 splicing, 11 deletions/insertion, 1 complex rearrangement, and
a chromosome 5 inversion that disrupts the gene sequence (81).
To date, only one HPS2 patient has been reported who devel-
oped HLH. However, since this patient also carried a potentially
contributing heterozygous RAB27A mutation, the risk to develop
HLH in HPS2 remains unclear (82). The pearl mouse model of
HPS2, upon infection with lymphocytic choriomeningitis virus,
developed all the key features of the disease, which yet was only
transient (82). In a cohort of 22 HPS2 patients, only one addi-
tional patient with HLH was identified; two developed incom-
plete, transient HLH-like episodes, although the cytotoxicity or
degranulation capacity was impaired in all 16 patients tested (83).
Although future reports might clarify the genotype–phenotype
correlations, the risk for HLH in HPS2 appears lower than in
Griscelli or CHS (79, 82).
CLINICAL PICTURE OF FHL
Most patients with FHL are brought to the attention of
the pediatrician because of long-lasting fever, which does not
respond to antibiotic therapy. Physical examination usually shows
hepatosplenomegaly (84); up to 30% of cases also show neuro-
logical abnormalities, from irritability to cranial nerve palsy or
seizures. Cerebrospinal fluid analysis shows alterations in more
than half of patients, with pleocytosis, increased protein, or both.
Several studies have defined the pattern of alterations evident
at neurologic imaging: parenchymal atrophy, diffuse abnormal
signal intensity in the white matter on T2-weighted images,
focal hyperintense lesions, delayed myelination, or parenchymal
calcification (85, 86).
Characteristic bio-markers are elevated ferritin, triglycerides,
α-chain of the soluble interleukin-2 receptor (sCD25), and low
fibrinogen. Hemophagocytosis by activated macrophages (which
became popular by being included in most of the different names
used for this disease since its original report in 1952) may be
lacking at initial bone marrow examination. This negative finding
does not preclude the diagnosis of HLH, as well as the presence of
hemophagocytosis alone does not make the diagnosis of HLH, and
should be considered supportive evidence only. Thus, the relevance
of hemophagocytosis in the set of diagnostic criteria might even
be questionable. Additional findings in a minority of patients are:
lymphadenopathy, icterus, rash, edema, high levels or transami-
nases, bilirubin, and lactate dehydrogenase. Accumulation of cases
allowed to characterize unusual presentations: acute liver failure
or isolated CNS involvement may be observed. This led to the
practice to consider HLH in the differential diagnosis of patients
scrutinized for possible liver transplant (87). Identification of high
levels of selected cytokines provided a likely explanation for some
clinical features: fever is induced by IL-1 and IL-6; pancytope-
nia results from high levels of IFN-γ and TNF-α and also from
hemophagocytosis; hypertriglyceridemia results from the inhibi-
tion of lipoprotein lipase by TNF-α; ferritin is secreted by activated
macrophages, also responsible for the high levels of plasminogen
activator, which cause high plasmin levels and hyperfibrinoly-
sis. The picture of the contribution of the individual cytokines
and chemokines is entirely under thorough evaluation by several
investigators.
DIAGNOSTIC STRATEGY
To facilitate an initial approach to the disease, in 1994 the Histio-
cyte Society defined a set of diagnostic criteria; they were subse-
quently revised in 2004 (Table 3) (88). Nevertheless, diagnosing
Table 3 | Revised diagnostic guidelines for hemophagocytic
lymphohistiocytosis (HLH).
The diagnosis of HLH can be established if either 1 or 2 below are fulfilled
1. A molecular diagnosis consistent with HLH
2. Clinical and laboratory criteria for HLH fulfilled (5/8 criteria below)
Fever
Splenomegaly
Cytopenia (affecting ≥2 of 3 lineages in peripheral blood)
Hemoglobin <9 g/dl (in infants <4 weeks: Hb <10 g/dl)
Platelets <100×109/l
Neutrophils <1.0×109/l
Hypertriglyceridemia and/or hypofibrinogenemia
Fasting triglycerides ≥3.0 mmol/l
Fibrinogen ≤1.5 g/l
Hemophagocytosis in bone marrow or spleen or lymph nodes
Low or absent NK cell activity
Ferritin ≥500µg/l
Soluble CD25 (i.e., soluble IL-2 receptor) ≥2,400 U/ml
Supportive evidences are cerebral symptoms with moderate pleocytosis and/or
elevated protein, elevated transaminases and bilirubin, LDH.
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FHL still represents a challenge for the pediatrician. Although most
of the cases develop the disease when they are very young, about
20% of cases only present once the subject is older than 2 years
(76); later onset, including the young adult age, is increasingly
reported (89–92). The information of parental consanguinity may
be useful but is expected in no more than 25% of cases. The family
history may include the early death of a sibling with undefined
cause, or diagnosed as “lymphoma or infection.” Evidence of par-
tial albinism, or “light hairs” is not frequent but, when present,
turns to be very informative.
The set of alterations described above, however are not specific.
Thus, in many cases leukemia is suspected at first but quickly ruled
out by bone marrow examination, which shows hemophagocytosis
in about one-half of all cases. Similarly, none of the biochemical
abnormalities described earlier are exclusive to HLH. Investiga-
tors wonder if these criteria might be simplified. The evidence
of defective NK cell activity, although very suggestive for the
diagnosis, is laborious and restricted to a limited number of labo-
ratories also due to the usual need for radionuclide reagents. The
real role of hemophagocytosis is repeatedly questioned. To this
issue, we observed that the combination of fever, splenomegaly,
and thrombocytopenia, in the absence of leukemia, represents the
starting point to suspect FHL (28). When this is associated with
hyperferritinemia, the clinician may consider it as a sufficient basis
to suspect HLH and thus address the diagnostic work-up already
within a few hours from admission (Figure 1). The level of D-
dimers is usually abnormal even when INR/PTT is normal. The
possible contribution of additional parameters, such as plasma
levels sCD25, sCD163, neopterin, and IFN-γ appears increasingly
convincing (86).
As in many other immune deficiencies, common pathogens,
especially viruses, may represent an excessive challenge for the
child with FHL and thus trigger the onset of the disease. It is very
important to remember that patients with visceral leishmaniasis
FIGURE 1 | Overview of the current diagnostic approach to FHL. The
clinical suspect is raised by a few elements, which may trigger the use of the
functional laboratory screening at flow-cytometry. Mutation analysis remains
the gold standard for confirmation of the diagnosis, with therapeutic
implications. Notes: 1. Some patients with pigment dilution syndromes (GS,
CHS, or HPS) may have gray or very blond hairs, not necessary albino
discoloration. 2. Although lack of SAP expression at flow-cytometry is
invariably associated with XLP-1, in rare cases patients with XLP-1 may have
residual, reduced, or even normal SAP expression; thus the 2B4 assay may be
used to discriminate between normal (activating 2B4) or defective (inhibitory
2B4) SAP function. 3. The use in flow-cytometry of currently available
anti-XIAP mAb does not provide fully satisfactory results, while it is more
suited for western blot analysis. Thus mutation analysis may be necessary to
rule out the diagnosis in the presence of suggestive clinical picture.
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may present with a very similar clinical picture (93), but espe-
cially in non-endemic areas this may not be readily included in the
differential diagnosis. Unfortunately, patients with undiagnosed
leishmaniasis have been diagnosed and then treated as FHL, with
major consequences. Thus, the use of polymerase chain reaction
(PCR) for investigation of selected infectious agents, including
EBV, cytomegalovirus (CMV), and Leishmania appears to be
recommended.
If a patient shows the set of initial parameters that match
the diagnostic hypothesis, such as fever, splenomegaly, thrombo-
cytopenia, and elevated ferritin, the attending physician should
approach an immunology laboratory, which is able to perform a
functional screening. Impaired NK cell cytotoxicity, measured as
lysis of K652 cells by peripheral blood lymphocytes in a standard
chromium release assay, became the hallmark of FHL. However,
the variability of NK cell percentages in PBL among different
individuals and the use of radioactivity present major limitations
to get precise and standardized results in different laboratories. The
use of the NK cytotoxicity assay is useful when it shows reduced or
absent activity, but normal NK function assay should not definitely
exclude the diagnosis of FHL.
Thus, a set of tools for the screening of FHL and other genetic
immune deficiencies associated with HLH has been developed. A
deficient intra-cytoplasmic expression of perforin by NK cells can
identify patients with FHL2 (14). Furthermore, defective intra-
cellular expression of SAP and XIAP are associated with XLP-1
and XLP-2, respectively. For patients with normal findings at the
above described assays, Marcenaro et al. have originally demon-
strated that surface CD107a expression represents a rapid tool for
identification of patients with degranulation defect (25). CD107a
(LAMP1) lines the lysosome containing perforin and granzymes to
prevent the NK and CTL itself from damage. After activation, the
granules move to the synapse with a fine-tuned process of polar-
ization and docking to the cell membrane. After the degranulation
into the synapse, CD107a can be identified on the surface of NK
and CTLs. Mutations of genes that produce proteins necessary for
this secretory mechanism result in the absence of CD107a mea-
sured by flow-cytometry. In FHL2, perforin is low or absent but
degranulation still takes place. Thus it is important to measure per-
forin expression before the degranulation assay is done. This is true
as well for XLP-1 and XLP-2 which are not associated with failure
of degranulation, and these proteins should be measured at least
in male patients with suspected genetic HLH. It is important to
note that although a minority of patients with a clinical diagnosis
of secondary HLH may have an abnormal resting NK cell degran-
ulation, none shows abnormal degranulation using interleukin-2
(IL-2)-activated NK cells (94).
A degranulation defect, which is present in the majority of FHL
cases,was first documented in patients with FHL3 (95), and rapidly
became the standard for their identification. Thereafter, additional
reports confirmed this finding also in patients with FHL4, FHL5,
GS2, CHS, and HPS2 (94). In patients with a high probability
for genetic defect, in whom flow-cytometry screening of relevant
molecules was normal, assessment of cytotoxic activity appears
mandatory. Repeated evidence for complete or partially defective
killing and/or degranulation should be taken as strong support for
the diagnosis of primary HLH (94). In addition, the clear evidence
of a functional defect can guide therapy even before a mutation is
identified.
Figure 1 describes an overview of our current diagnostic strat-
egy for FHL. In summary, these assays provide an initial confir-
mation of the clinical diagnosis, and direct the mutation analysis,
which yet remains the gold standard for the diagnosis. In 80% of
familial HLH cases the genetic error can be identified by sequenc-
ing. Knowledge of the genetic background has a great impact on
the treatment of the patient: it supports indication towards HSCT,
helps with the selection of a matched donor, and represents a use-
ful tool to counsel the family, and to offer prenatal diagnosis if
requested.
TREATMENT OF FHL
Historical reports showed that patients with HLH have an
exceedingly high risk of mortality within weeks (84), unless an
appropriate treatment is started promptly. According to the patient
condition, the treatment may be started even before the results
from some diagnostic studies become available. The immediate
aim of therapy is to suppress the hyper-inflammatory state and to
kill not only the exuberant lymphocytes, but also the pathogen-
infected antigen-presenting cells. This removes the stimulus, thus
breaking the vicious loop of continuous but ineffective activa-
tion of cytotoxic cells. The first international cooperative study
HLH94 set the combination of dexamethasone and etoposide as
the standard of care (88, 96). This strategy brings most patients
into a state of disease control within 4–8 weeks. This may buy
enough time for further diagnostic tests. For those patients with
evidence of a genetic defect, HSCT is strongly recommended, it
being the only treatment that can cure FHL to date. Yet, this
is not an easy and universal solution. Although recent advances
in transplantation procedures and supportive therapy minimize
the transplant-related mortality, this is particularly true for 20%
of the patients who have a matched familial donor, the pro-
cedure remains risky and by no means a guarantee for sur-
vival. For the remaining cases, a matched unrelated, or partially
matched familial donors, or cord blood units, are the possible
alternative sources for HSCT. Since treatment related mortality
in this setting remains a big threat, it is extremely important
that a recommendation for HSCT is correctly defined. The use
of RIC for HSCT provided a significant improvement especially
by reducing the unacceptably high level of toxicity connected
with the use of ablative regimens (and in particular the veno-
occlusive disease resulting from exposure to busulphan) (97, 98).
Although the use of RIC may be associated with incomplete
donor chimerism, the use of anti-thymoglobulin (ATG) or alem-
tuzumab and fine tuning of its timing has considerably improved
the treatment results (99). Moreover, as in other constitutional
or acquired immune disorders, mixed chimerism may turn out
to be sufficient to control the disease by replacing the defective
function (100, 101).
For patients with normal function at initial screening, the
current treatment strategy also suggests to allow a chance
for treatment withdrawal after disease resolution in order to
avoid, potentially unnecessary, HSCT. For patients with refrac-
tory disease or with disease reactivation, which appear unable
to remain disease-free in the absence of chemo-immunotherapy,
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transplantation will be considered even in the absence of a
documented genetic defect.
One major problem in the cure of patients with FHL remains
the persistent, unacceptably high rate of mortality in the early,
pre/transplant phase. In 1993, Stephane et al. (102) reported
an ATG-based regimen associated with a more rapid response
rate, explained by its direct attack of CTL, which are thought
to drive the disease process. These data were updated and
expanded by the same group in 2007 (103). Unfortunately, this
regimen may lead to shorter remissions and higher reactiva-
tion rates, when compared to the standard etoposide-based regi-
men. Because these two regimens have complementary strengths
(and weaknesses), a pilot study has been designed to adopt a
hybrid regimen, which combines initial ATG with subsequent
weekly doses of etoposide. This approach has been adopted in
a pilot study run in parallel in Europe and in the USA, under
the name EURO-HIT-HLH (EudraCT Number 2011-002052-
14) and HIT-HLH (ClinicalTrials.gov Identifier: NCT01104025),
respectively.
Furthermore, data derived from the animal model suggest that
blocking the IFN-γ activity may induce disease control without
cytoreduction. Thus, the feasibility and the therapeutic potential
of a novel human anti-IFN-γ agent denominated NI-05-01 is cur-
rently explored in a phase II study run on an international setting
(EudraCT Number 2012-003632-23).
Finally, the hypothesis to cure patients with FHL using gene
transfer is supported by its monogenic origin. To this issue, the
recent report that gene transfer corrects the cellular and humoral
defects in SAP(−/−) mice provides proof of concept for gene
therapy in XLP-1 (104).
MACROPHAGE ACTIVATION SYNDROME
Children and adults with autoimmune diseases, especially systemic
onset juvenile idiopathic arthritis (s-JIA), may develop a clinical
syndrome closely resembling, or even overlapping, HLH. This con-
dition has been repeatedly defined as “macrophage activation syn-
drome” (MAS). Specific diagnostic criteria for MAS complicating
JIA have been developed. In particular, persistent continuous fever
≥38°C, falling leukocyte count, falling platelet count, increased
liver enzymes, hyperferritinemia, falling erythrocyte sedimenta-
tion rate, hypofibrinogenemia, hypertriglyceridemia, and evidence
of hemophagocytosis in the bone marrow characterize severe MAS
(105). About 7% of patients with JIA develop life-threatening
MAS (105–107). Although treatment with immunoglobulin and
cyclosporine A has been defined as the current standard for MAS,
in some patients a more aggressive therapy, similar to that of HLH,
may be required. Several cases of s-JIA-associated MAS dramati-
cally benefiting from the IL-1 receptor antagonist, anakinra, after
inadequate response to corticosteroids and cyclosporine A have
now been reported (108). It is noteworthy that, although most
patients with MAS have normal or reduced NK cell function, they
show reduced expression of perforin or SAP, and heterozygous
mutations in one FHL-related genes (109–111), thus launch-
ing a bridge between FHL and the pathogenic mechanisms of
MAS. Attempts to harmonize the nomenclature between HLH
and MAS are ongoing in cooperation by pediatric hematologists
and rheumatologists.
VARIANT PHENOTYPES RECOGNIZED IN ASSOCIATION
WITH PARTIAL CYTOTOXIC DEFECTS
Whereas the complete cytotoxic defect, due to biallelic disruptive
mutations in one of the FHL-related genes, leads to full-blown
FHL, with the typical and rapidly fatal course, the clinical impact
of a less complete or partial defect in this pathway remains yet to
be clarified.
However, over the last years, reports of later onset of FHL up
to adult age and associations between monoallelic mutations of
the FHL-related gene and conditions other than FHL suggest that,
although far from causing the full-blown picture of FHL, partial
insufficiency of the cytotoxic machinery could pave the way to
alternative phenotypes.
LATER ONSET OF FHL
The age at diagnosis of FHL is usually very young, with a peak inci-
dence between 1 and 6 months of age (84). Nevertheless, over the
years sporadic cases of FHL in older patients have been reported,
pointing to unexpected later onset. In 2001, Allen et al. reported
four familial cases of HLH diagnosed on a clinical basis, at an age
comprised between 9 and 17 years (89). Soon after, Clementi et al.
described the first adult cases in two siblings developing FHL2 at
22 and 21 years of age (91). This was followed by other reports of
FHL2 in older children or adolescents of different ethnic origins:
one 7-years-old patient from Russia, two North American patients
of 8 and 10 years (17), one 10-year-old Turkish patient (9), three
Japanese patients of 7–12 years (112), and more recently, three
Columbian patients aged 5–12 years (113). The oldest patients
reported to date are a Spanish man of 49 years, homozygous for
PRF1 A91V (114), and a 62-year-old Japanese man, compound
heterozygous for a PRF1 missense and a non-sense mutation (115).
In 2011, Zhang et al. described 10 adult patients with FHL due
to biallelic mutations in PRF1 (n= 7), MUNC13-4 (n= 2), and
STXBP2 (n= 1) (24), showing that not only FHL2 could present
later in the life.
Despite these sporadic reports, adult patients are still at most
considered as affected by the “secondary” non-genetic form of
HLH, which has several implications in treatment and outcome.
Thus, with the aim to raise the attention of adult specialists to
this rare disease we recently described our experience in diag-
nosing FHL in subjects older than 18 years in Italy. Out of the
197 patients referred to the Italian Registry of HLH in which a
genetic defect in FHL-related genes had been identified, 11 (6%)
were older than 18 years with a median age of 23 years (range, 18–
43 years). FHL2 was the most frequent subtype (n= 6) with A91V
the most frequent single mutation. The other genetic diagnoses
were: FHL3 (n= 2), FHL5 (n= 1), XLP-1 (n= 2). Only one-half
of these patients presented with the full-blown picture of HLH,
while the other half had atypical manifestations at the onset, which
brought them often to the attention of non-hematological spe-
cialists. This led to frequent delay in diagnosis and treatment. The
clinical course was aggressive and led to early death in 8 of 11
(72%) patients supporting the indication to treat these patients
until HSCT (92).
To our knowledge, all the patients with later onset of FHL
reported to date have at least one missense mutation, while none
had biallelic disruptive mutations. This is in keeping with the
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results of the genotype–phenotype studies of FHL, which estab-
lished a close correlation between biallelic disruptive mutations
and early age at the onset of FHL (10, 28). Thus, we can specu-
late that in the presence of hypomorphic genetic defects, residual
protein allows some level of NK- and T-cell function, sufficient to
cope with common infectious agents, the usual triggers of FHL,
at least for several, or even many years. This is also described
in a gene-expression profiling study showing that patterns of up-
and down-regulated genes separated patients with“late-onset”and
“relapsing” forms of FHL from patients with an “early onset and
rapidly evolving” form of the disease (116).
ASSOCIATION BETWEEN MONOALLELIC MUTATIONS OF FHL-RELATED
GENES AND CONDITIONS OTHER THAN FHL
Cellular cytotoxicity by NK cells and CTLs plays a central role in
immune surveillance and tolerance through granule-dependent
exocytosis pathway or death-receptor pathway. This gave rise to
association studies aimed at investigating if genes involved in pro-
gramed cell death of lymphocytes could contribute to cancer and
autoimmune susceptibility (117).
Lymphoma
The description of the association between different kind of lym-
phoma and HLH (118, 119) has been followed by studies reporting
the link between monoallelic PRF1 mutations and lymphomas
(120–124). Lymphoma or HLH was reported in two siblings
with PRF1 mutations (91), and then autoimmune lymphopro-
liferative syndrome and lymphoma in a patient with heterozy-
gous Fas and PRF1 mutations (122). Later on, Clementi et al.
described four patients with Hodgkin or non-Hodgkin lymphoma
who had biallelic perforin mutations and four additional patients
with monoallelic PRF1 mutations (123). A possible predispos-
ing role of PRF1 variants for ALCL was later established, with
the finding of mutations in 27% of children with this subtype
of lymphoma (124). We recently decided to extend this study to
a larger, unselected population of children with ALCL, and to
investigate them for even other FHL-related genes. In line with
the previous data, 23 of the 84 (27%) children with ALCL were
found to have monoallelic mutations in one of three genes: 21
patients (25%) carried a total of 10 different mutations of PRF1,
2 additional patients had missense mutations of the UNC13D
gene, but no mutations were found in the gene SH2D1A. The
observation that PRF1 is involved in a quarter of patients with
ALCL suggests a correlation between insufficient cellular cyto-
toxicity and development of ALCL. Less frequent involvement of
UNC13D may suggest that subjects heterozygous for mutations in
this gene may have others escape mechanisms to prevent lym-
phoma. SH2D1A, the XLP-1 gene, is not related to childhood
ALCL (125). Yet, the observation that 5 of 158 males present-
ing with B-cell NHL (3.2%) had SH2D1A mutations raises the
issue of prospective screening for XLP-1 in males with B-cell
lymphoma (126).
As an extension of their previous association study on lym-
phoma, Santoro et al. in 2005 sequenced PRF1 in 100 children
with acute lymphoblastic leukemia detecting the most frequent
PRF1 mutation (A91V) in 12/100 patients and 5/127 controls
(p= 0.014) (19). A similar study of the Cincinnati group, on a
much larger cohort, confirmed this association only for BCR-ABL
positive acute lymphoblastic leukemia (127).
The role of PRF1 mutations in the predisposition to cancer has
been addressed repeatedly especially by the Australian group. In a
first study they analyzed 23 individuals with biallelic PRF1 muta-
tions whose onset of FHL was delayed or abolished and found that
11/23 presented as the primary clinical illness with B- or T-cell
lymphoma or acute or chronic leukemia (128). In the following
study of 81 European or Maghrebian families in which hematolog-
ical malignancies had been diagnosed, they found that 3.7% had a
PRF1 variant. The A91V mutation and the N252S polymorphism
were already known, while the novel A211V missense substitu-
tion was observed in two related Tunisian patients. However, they
also report that the lytic function of perforin was not affected
by over-expression of mutated PRF1 in rat basophilic leukemia
(119). Subsequently they examined the effect of perforin defi-
ciency in four models of mouse B-cell lymphomagenesis. Perforin
was shown to act as a suppressor of B-cell malignancies charac-
teristically driven by v-Ablor bcl-2, whereas Mlh loss cooperated
in accelerating spontaneous B-cell lymphomas characteristic of
pfp loss. No protective role for perforin was observed in the more
aggressive E-myc model of B-cell lymphoma. These transgenic
models have allowed to pinpoint the role of perforin in surveillance
of B-cell lymphomagenesis (129).
Autoimmune lymphoproliferative syndromes
Following the previous identification of a heterozygous muta-
tion of PRF1 in an autoimmune lymphoproliferative syndromes
(ALPS) patient, in 2006 Clementi et al. analyzed 14 ALPS and 28
Dianzani autoimmune lymphoproliferative disease (DALD) cases
and found a different amino-acid substitution in 2 of 14 ALPS and
6 of 28 DALD. This suggested that variations in genes involved in
the cytotoxicity of CTL and NK cells may also influence ALPS and
DALD presentation (130). To assess the potential role of UNC13D
gene in the susceptibility to ALPS and DALD, Aricò et al. recently
sequenced UNC13D in 21 ALPS and 20 DALD patients detect-
ing 4 rare missense variations in 3 heterozygous ALPS patients.
Transfection of the mutant cDNAs into HMC-1 cells showed that
they decreased granule exocytosis, compared to the wild-type con-
struct. These data suggested that rare loss-of-function variations
of UNCD13D are risk factors for ALPS development (131).
Boggio et al. analyzed SH2D1A in ALPS and DALD patients
based on the observation of Komori et al. (132) that suggested an
opposite epistatic relationship between the Fas and SAP defects
in mice. They found that ALPS and DALD patients displayed
an increased frequency of the 346T single nucleotide polymor-
phism (SNP) in SH2D1A causing a loss of the−346°C methylation
site and correlating with increased SAP expression and decreased
IFN-γ production. Based on this finding they suggested high
SAP expression promotes development of ALPS and DALD in
human (133).
Multiple sclerosis
The screening of PRF1 mutations in 1,156 patients with multi-
ple sclerosis showed a higher frequency of monoallelic or bial-
lelic A91V mutations compared to the control group (1,788
subjects) (134).
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Arthritis and other rheumatologic disorders
Several groups have reported decreased levels of perforin in CTLs
and in particular NK cells, along with decreased NK cell function
in patients with s-JIA (109, 110). The first case of association of
s-JIA and FHL-related genes was reported by Hazen et al. in 2008,
who described an 8-year-old girl with s-JIA and hemophagocy-
tosis, without complete criteria of MAS, who was found to have
compound heterozygous mutations of UNC13D and reduced NK
cell cytotoxic function (135). Soon after, variations in UNC13D
were identified in 3/18 patients with s-JIA/MAS of which two
had biallelic mutations (136). Starting from this, Vastert et al.
sequenced PRF1 in 54 s-JIA patients: 11 of 56 (20%) patients were
heterozygous for missense mutations in PRF1, and s-JIA patients
with history of MAS presented an increased prevalence of A91V
mutation (20%) compared with s-JIA patients without history of
MAS (9.8%) (137). Recurrent MAS was recently associated with
monoallelic W374X mutation in PRF1 in a child with s-JIA (111).
Other associations
Mutations in the PRF1 gene were also detected in one 4-year-old
girl with primary necrotizing lymphocytic CNS vasculitis (138)
and in an 11-year-old girl with panniculitis. They were biallelic in
the first case, monoallelic in the second one (139). Pasqualini et al.
recently reported an 11-year-old boy with a history of secondary
HLH who developed cytophagic histiocytic panniculitis, in whom
mutation analysis showed monoallelic missense mutation of the
STX11 gene (140).
The investigation of PRF1 in type I diabetes showed that allelic
frequency of N252S was significantly higher in patients than in
controls (141).
X-linked inhibitor of apoptosis protein mutations have been
proposed to be involved in other phenotypes. Weiss et al. pro-
posed XIAP as a putative modifier gene in Wilson disease (142).
Ferretti et al. suggested a role of XIAP variants as a predisposing
factor for idiopathic periodic fever (IPF) development, possibly
through its influence on monocyte function. They evidenced a
polymorphism, P423Q, at higher frequency in a large cohort of
IPF patients. They also demonstrated that 423Q allele, as compared
with 423P, was associated with higher Xiap protein and messenger
RNA expression and lower caspase 9 activation (143). Recently,
Ou et al. genotyped the XIAP Q423P polymorphism in 100 pedi-
atric patients diagnosed with HLH and found its frequency to be
comparable in patients and healthy controls (144).
Although association studies should always be taken with cau-
tion, unless investigation documents its pathogenic value in this
specific condition, taken together these data indicate that some-
times different phenotypes can be associated to monoallelic or pre-
sumably “hypomorphic” mutations of FHL-related genes. In par-
ticular, a partial defect of granule-dependent cytotoxicity appears
to be involved in the predisposition to cancer and autoimmunity,
suggesting a link between these different pathogenic pathways and,
likely, the role of other yet unknown genes.
CONTRIBUTION OF FHL PATIENTS TO THE CLARIFICATION OF
THE CYTOTOXIC MACHINERY
In the granule-dependent exocytosis pathway, target cell recog-
nition by CTL and NK cells is followed by the polarized release
of preformed cytolytic granules into the synaptic cleft formed
between the effector and the target. Exocytosis of mature cytolytic
granules from CTL and NK cells is a complex phenomenon and
key for the clearance of virally infected or tumorigenic cells. The
process that leads to fusion of cytolytic granules at the immuno-
logical synapse can be divided into four distinct steps: polarization,
docking, priming, and fusion of cytolytic granules. The analysis of
patient CTL and NK cells, the morphological comparison to cells
from healthy individuals, assessing their ability to form cytotoxic
granules and to polarize and secrete these has been critical to gain
an insight into the molecular machinery that drives CTL and NK
cell cytotoxicity. Only by careful analysis of patient CTL and NK
cells we can now draw a molecular picture of how mutations in
proteins hamper normal CTL and NK cell function (Figure 2).
Mutations in the small cytoplasmic signaling adaptor pro-
tein SAP (XLP-1) affect activation of NK cells. SAP associates
with members of the SLAM family of trans-membrane recep-
tors, including SLAM (CD150), LY9 (CD229), CRACC (CD319),
CD84, NTB-A (CD352), and 2B4 (CD244) (145). 2B4 is a co-
receptor expressed in NK and T lymphocytes and specifically rec-
ognizes CD48, which is present solely on hematopoietic cells. 2B4
engagement causes tyrosine phosphorylation of immune receptor
tyrosine-based switch motifs (ITSM), recruitment of SAP and thus
transduction of activating signals via Fyn-dependent processes
(145, 146). In the absence of functional SAP, 2B4 associates with
protein tyrosine phosphatases and delivers inhibitory signals (53,
55, 147). Consequently, lack of NK cell-mediated cytotoxicity in
XLP-1 mainly stems from the inhibitory effect of 2B4, which, upon
engagement by CD48 (up-regulated on B-EBV cells), impairs the
function of activating receptors (52). Beyond their common chro-
mosomal localization and their requirement for normal immune
responses to certain viral infections, SAP and XIAP showed no
structural or functional similarity, are not co-regulated, and do
not appear to directly interact (65). SAP functions as an intracel-
lular adaptor molecule involved in SLAM family signaling (51).
XIAP is an inhibitor of apoptosis family member, known for its
caspase-inhibitory and anti-apoptotic properties. In patients with
SAP deficiency, HLH may develop for several reasons including
absence of iNKT cells and defective T-cell reactivation-induced
cell death (148–150). The mechanism involved in XIAP deficient
patients is still unclear.
Activation and priming of NK and CTL leads to the formation
of secretory lysosomes, which contain lytic molecules including
perforin, granzymes (a family of serine proteases), granulysin,
and other lysosomal enzymes, but also a proteoglycan matrix
(serglycin) that maintains proteases in an inactive stage, per-
forin inhibitor (calreticulin), and Fas ligand. CTL from CHS
patients, however, show enlarged lysosomal compartments with
ER-specific membrane proteins and autophagic inclusions, indi-
cating a function of Lyst during lysosomal fission (151, 152). Why
these enlarged lytic granules fail to fuse is still not fully under-
stood. It could be that the structures are simply too big to polarize
and fuse.
Similar to the function of Lyst, the AP-3 complex is also
required for proper lytic granule maturation in CTL. Defects
in the β-3A subunit disrupt the entire AP-3 complex, lead
to lysosomal protein mis-sorting in some cell types including
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FIGURE 2 | Familial hemophagocytic lymphohistiocytosis and the
immunological synapse. (A) Simplified model of an NK cell synapse formed
by a healthy (left) or SAP-deficient (right) cell. In a healthy NK cell, SAP binds
to the cross-linked and phosphorylated 2B4 receptor, which leads to the
recruitment of Fyn and consequently lysis of the target cell. In the absence of
SAP, 2B4 associates with protein tyrosine phosphatases (SHP-1, SHP-2, and
SHIP) delivering inhibitory signals. (B) Cartoon of a CTL synapse to illustrate
the granule maturation and polarization defect observed in CHS and HPS2
patients, respectively. (C) Magnification of the CTL: target synapse area from
(B), depicting the docking defect observed in GS2 patients, the molecular
function of Munc13.4 in granule maturation and priming, which is impaired in
FHL3 patients, and lack of perforin in the granules of FHL2 patients. (D) Model
illustrating the fusion of membranes by the activity of SNARE proteins (such
as syntaxin 11) and Munc18-2, which is lost in FHL4 and FHL5 patients.
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melanosomes and platelets, as well as CTLs and NK cells (153,154).
In melanocytes AP-3 sorts tyrosinase and melanin-processing
enzymes into melanosomes (155). However, the exact molecu-
lar function of AP-3 during secretory lysosome maturation in
CTL and NK cells is not yet fully understood. Phenotypically,
HPS2 patient cells show an increase in tubular–vesicular endo-
somes and secretory lysosomes that fail to polarize to the IS (156,
157). These observations suggest a role of AP-3 in the trafficking
of a microtubule motor protein or its adaptor to secretory lyso-
somes (80). Interestingly, most HPS2 patients only show a mild
HLH phenotype posing the question whether residual amounts
of functional AP-3 are sufficient to sustain CTL and NK cell func-
tion, or whether loss of AP-3 may be compensated for by a different
adaptor protein (157).
Once polarized, secretory lysosomes in healthy CTL dissociate
from the microtubules and dock at the immunological synapse. In
Rab27a-deficient GS2 patient CTL secretory lysosomes polarize
normally at the immunological synapse but then remain attached
to the microtubules, resembling beads on a string (158), providing
evidence that Rab27a facilitates granule detachment and docking.
Interestingly, loss of Munc13-4 from CTL impairs secretion at a
similar stage; however, in contrast to GS2, secretory lysosomes
in Munc13-4-deficient CTL detach from the microtubules and
dock, but fail to fuse with the plasma membrane (95, 158). Taken
together, these morphological phenotypes suggest that Rab27a
and Munc13-4 function in consecutive steps during cytotoxicity,
by mediating lytic granule docking and priming, respectively; a
hypothesis strengthened by the finding that Rab27a and Munc13-4
interact directly (159–162).
As a member of the Rab family, the small guanine nucleotide-
binding protein Rab27a operates as a molecular switch, and by
that can controls a myriad of cellular processes. Besides the
interaction with Munc13-4, active Rab27a also binds a class of
proteins that is closely related to neuronal synaptotagmin I: the
synaptotagmin-like proteins (Slps) (163). In melanocytes, Rab27a
binds the synaptotagmin-like protein melanophilin and the plus-
end directed actin motor myosin Va (164–166). This complex
facilitates the polarization and docking of melanosomes at the
cell’s periphery and explains why loss of functional Rab27a causes
albinism. In CTL, however, active Rab27a appears to interact
with various, functionally redundant Slps (namely Slp1, Slp2a,
and Slp3) since only over-expression of a dominant-negative con-
struct against the highly conserved SHD domain of these Slps
resulted in a striking cytotoxicity phenotype (165, 167–169). It is
conceivable that Slp1, Slp2a, and Slp3 act as vesicle tethers at the
plasma membrane or form the linker between Rab27a and a motor
protein.
Munc13-4 is one of four mammalian homologs of C. elegans
Unc13 (170). Munc13 proteins vary significantly in size and in
the number of functional domains; however, the C-termini of all
Munc13 proteins are highly homologous, encoding the recently
defined MUN domain (171). One role fulfilled by Munc13-4 is that
of a vesicle tether, arresting the movement of Rab27a-positive vesi-
cles at the site of secretion and enabling vesicle priming (161, 172).
This function is most likely exerted by the central MUN domain,
due to its similarity to vesicle tethering proteins Sec6p and Vps53
(173–175). Moreover, Munc13-4 was recently shown to interact
with the SNARE domain of Stx11 and t-SNARE complexes, thus
offering a mechanism by which Munc13-4 could mediate vesicle
priming and initiate fusion (176).
Besides its role as tether/priming component, which depends
on the interaction with Rab27a, Munc13-4 has also been con-
nected to lytic granule maturation in a Rab27a-independent
mechanism by facilitating fusion between two distinct endosomal
compartments (162). This model suggests that cytolytic granules
in Munc13-4-deficient CTL lack the necessary fusion machinery,
explaining why vesicle release is arrested after docking.
The final step during cytotoxicity is the release of cytotoxic
mediators into the cleft between CTL and the target cell; a process
that is facilitated by SNARE proteins, as well as SNARE accessory
proteins (177). Stx11 is an unusual member of the syntaxin fam-
ily of SNARE proteins as it associates with membranes through a
cysteine-rich region at its C terminus, instead of the C-terminal
trans-membrane domain (178). It still remains elusive whether
lipid anchored SNARE proteins can facilitate membrane fusion,
with reports arguing both ways (178–181). It is conceivable that
Stx11 may form inhibitory, fusion incapable SNARE complex,
potentially with Vti1b, and thus regulate membrane fusion indi-
rectly. However, the observation that Stx11 can also form a SNARE
complex with SNAP23 and VAMP8, which itself is crucial for CTL
cytotoxicity (34, 182), supports an active role of Stx11 during
membrane fusion.
Much of the molecular function of Stx11 depends on Munc18-
2, another critical component of the CTL fusion machinery. One
of the functions of Munc18-2 is to chaperone Stx11 as shown
by reduced protein levels of Stx11 in Munc18-2-deficient CTL
(40, 41). This role depends on the direct interaction between
Munc18-2 and Stx11 and is most likely initiated and selected
for by the N peptide of Stx11. Strikingly, the killing defect
observed in CTL and NK cells from FHL4 and FHL5 patient
can often be compensated for by in vitro activation with IL-2
(40, 41, 43, 46). This may be partially due to the up-regulation
of surrogate proteins, namely Stx3 and Munc18-1. Interestingly,
in the absence of Stx11 Stx3 is trafficked to the plasma mem-
brane in a Munc18-2-dependent manner, adding evidence to
the model that Stx11 is indeed involved in the final fusion
event (183). Besides the chaperone function, detailed analysis of
reported mutations additionally concluded that Munc18-2 will
most likely function during SNARE complex formation, binding
and fusion itself, similar to the role of its homolog Munc18-1 in
neurons (184–186).
CONCLUSION
Familial hemophagocytic lymphohistiocytosis is a rare, life-
threatening disease with a non-specific clinical presentation,
which needs accurate clinical, immunological, and genetic diag-
nostic work-up. Current standard of therapy based on chemo-
immunotherapy (dexamethasone and etoposide) allows rapid dis-
ease control in most but not all patients. Due to the remaining risk
of early mortality, novel therapeutic approaches based on the use
of anti-thymocyte globulin (ATG or anti-CD52/Campath), or an
anti-IFN-γ human monoclonal antibody, are currently explored
in international cooperative settings. Currently identified genetic
defects allow the assignment of a genetic marker to over 80%
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of the families, with proportions varying according to the geo-
graphic areas. In the remaining patients, some cases show either
familial recurrence and/or the disease is refractory or recurs after
initial treatment; these items strongly suggest an additional genetic
defect beyond the ones we currently investigate. All such cases
should be addressed to reference laboratories with research capa-
bilities, where the combined use of confocal microscopy, cellular
cytotoxicity assays, and protein expression studies may help to bet-
ter characterize putative novel defects. In turn, those studies will
broaden our current knowledge of the cellular cytotoxic machin-
ery in humans. In the meanwhile, observations of mono or even
biallelic mutations in FHL-related genes in patients with pheno-
types different from FHL, may provide additional insights into
our understanding of the role of this part of innate and adaptive
immunity.
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